| Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas LV Pham, S Huang, H Zhang, J Zhang, T Bell, S Zhou, E Pogue, Z Ding, ... Clinical Cancer Research 24 (16), 3967-3980, 2018 | 88 | 2018 |
| Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma J Lee, LL Zhang, W Wu, H Guo, Y Li, M Sukhanova, G Venkataraman, ... Blood Advances 2 (16), 2039-2051, 2018 | 59 | 2018 |
| B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy L Zhang, K Nomie, H Zhang, T Bell, L Pham, S Kadri, J Segal, S Li, ... Clinical Cancer Research 23 (15), 4212-4223, 2017 | 55 | 2017 |
| miR-888 in MCF-7 side population sphere cells directly targets E-cadherin S Huang, M Cai, Y Zheng, L Zhou, Q Wang, L Chen Journal of Genetics and Genomics 41 (1), 35-42, 2014 | 32 | 2014 |
| Pleiotropic action of novel Bruton's tyrosine kinase inhibitor BGB-3111 in mantle cell lymphoma CJ Li, C Jiang, Y Liu, T Bell, W Ma, Y Ye, S Huang, H Guo, H Zhang, ... Molecular cancer therapeutics 18 (2), 267-277, 2019 | 28 | 2019 |
| A natural allele of OsMS1 responds to temperature changes and confers thermosensitive genic male sterility L Wu, X Jing, B Zhang, S Chen, R Xu, P Duan, D Zou, S Huang, T Zhou, ... Nature communications 13 (1), 2055, 2022 | 23 | 2022 |
| Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma J Wang, J Wang, E Lopez, H Guo, H Zhang, Y Liu, Z Chen, S Huang, ... Blood cancer journal 9 (12), 95, 2019 | 22 | 2019 |
| The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma S Huang, C Jiang, H Zhang, T Bell, H Guo, Y Liu, Y Yao, D Zeng, ... Blood cancer journal 8 (3), 33, 2018 | 22 | 2018 |
| Super-resolution imaging of the natural killer cell immunological synapse on a glass-supported planar lipid bilayer P Zheng, G Bertolet, Y Chen, S Huang, D Liu JoVE (Journal of Visualized Experiments), e52502, 2015 | 22 | 2015 |
| Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma H Guo, D Zeng, H Zhang, T Bell, J Yao, Y Liu, S Huang, CJ Li, E Lorence, ... Oncogene 38 (11), 1802-1814, 2019 | 21 | 2019 |
| MiR-888 regulates side population properties and cancer metastasis in breast cancer cells S Huang, L Chen Biochemical and Biophysical Research Communications 450 (4), 1234-1240, 2014 | 18 | 2014 |
| PD-1 blocks lytic granule polarization with concomitant impairment of integrin outside-in signaling in the natural killer cell immunological synapse Y Huang, Z Chen, JH Jang, MS Baig, G Bertolet, C Schroeder, S Huang, ... Journal of Allergy and Clinical Immunology 142 (4), 1311-1321. e8, 2018 | 16 | 2018 |
| PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma S Huang, Y Liu, Z Chen, M Wang, VC Jiang American Journal of Cancer Research 12 (3), 1102, 2022 | 12 | 2022 |
| Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models Y Zhou, C Fu, Y Kong, D Pan, Y Wang, S Huang, Z Li, Z Ning, X Lu, ... Anti-cancer drugs 30 (9), 909-916, 2019 | 12 | 2019 |
| Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma VC Jiang, Y Liu, J Lian, S Huang, A Jordan, Q Cai, R Lin, F Yan, ... The Journal of clinical investigation 133 (3), 2023 | 10 | 2023 |
| Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis S Shan, Y Zhou, J Yu, Q Yang, D Pan, Y Wang, L Li, J Zhu, Y Zhang, ... International Immunopharmacology 77, 105914, 2019 | 8 | 2019 |
| Targeting PI3K and PLK1 to overcome ibrutinib-venetoclax resistance in mantle cell lymphoma C Jiang, R Zhang, S Zhang, W Lee, S Huang, Y Liu, A Leeming, ... Blood 134, 4062, 2019 | 8 | 2019 |
| Resistance mechanisms underlying venetoclax resistance in mantle cell lymphoma S Huang, C Jiang, H Guo, J Wang, Y Liu, C Li, E Lopez, H Zhang, ... Blood 130, 2749, 2017 | 8 | 2017 |
| IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO ML Wang, H Lee, S Thirumurthi, H Chuang, F Hagemeister, J Westin, ... Hematological Oncology 35, 142-143, 2017 | 7 | 2017 |
| Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma VC Jiang, Y Liu, A Jordan, A Leeming, J McIntosh, S Huang, R Zhang, ... Journal of Hematology & Oncology 15 (1), 42, 2022 | 6 | 2022 |
Yang LiuMD Anderson Cancer CenterVerified email at mdanderson.org
